You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,172,921


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,172,921
Title:Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
Inventor(s): Couvineau; Alain (Paris, FR), Voisin; Thierry (Paris, FR), Messal; Nassima (Paris, FR), Ogier-Denis; Eric (Paris, FR), Treton; Xavier (Paris, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)
Application Number:15/320,827
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,172,921

Introduction

When analyzing a patent, such as United States Patent 10,172,921, it is crucial to delve into the specifics of the claims, the broader patent landscape, and the legal and regulatory frameworks that govern patent law. This analysis will cover the key aspects of patent claims, the types of patentable subject matter, the role of the USPTO, and the implications of recent judicial and administrative developments.

Understanding Patent Claims

Patent claims are the heart of any patent application, as they define the scope of the invention for which protection is sought. For a patent like 10,172,921, the claims must be clear, concise, and definite to meet the requirements of 35 U.S.C. ยง112(b)[2].

Types of Patentable Subject Matter

The Patent Act, specifically Section 101, outlines the categories of inventions that can be patented: processes, machines, manufactures, and compositions of matter. However, not all inventions fall within these categories. The Supreme Court has established implicit exceptions, excluding laws of nature, natural phenomena, and abstract ideas from patentability unless they are transformed into a patent-eligible application through an inventive concept[2].

The Role of the USPTO

The United States Patent and Trademark Office (USPTO) plays a critical role in evaluating patent applications. The USPTO has issued guidance, such as the 2019 Guidance, to clarify how to apply the Alice/Mayo framework for determining patent-eligible subject matter. This guidance has particularly impacted the patentability of computer-related inventions, including those involving artificial intelligence (AI)[2].

The Alice/Mayo Framework

The Alice/Mayo framework is a two-step test used to determine whether a patent claim is directed to an ineligible concept. First, it must be determined if the claim is directed to a law of nature, natural phenomenon, or abstract idea. If so, the second step assesses whether the claim contains an inventive concept that transforms the nature of the claim into a patent-eligible application. This framework has been pivotal in recent Supreme Court decisions, narrowing the scope of patent-eligible subject matter[2].

Impact of AI on Patentability

With the increasing use of AI tools in patent drafting and invention, the USPTO has issued additional guidance. If an AI tool is material to patentability, its use must be disclosed. This includes scenarios where an AI system assists in drafting the patent application or introduces alternative embodiments not conceived by the inventor. Ensuring that human inventors significantly contribute to the claimed invention is crucial[5].

Patent Assertion Entities (PAEs)

PAEs, also known as "patent trolls," can significantly impact the patent landscape. The FTC has identified two main business models for PAEs: Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses for large portfolios without necessarily litigating, while Litigation PAEs often precede licensing with patent infringement suits. These entities can affect various industries, including retail trade, and their activities can have substantial economic implications[3].

Trademark Law and Distinctiveness

While patent law deals with inventions, trademark law protects brand identities. The Lanham Act governs federal trademark protection, emphasizing the distinctiveness of marks. Marks can be generic, descriptive, suggestive, arbitrary, or fanciful, with the most distinctive marks being eligible for the principal register. Descriptive marks, however, require acquired distinctiveness or secondary meaning to be registrable[1].

Case Study: Booking.com

The Supreme Court's decision in Patent and Trademark Office v. Booking.com B.V. highlights the importance of consumer perception in trademark law. The court held that "Booking.com" is not generic and can be registered as a trademark because it has acquired distinctiveness in the minds of consumers. This case underscores the significance of the primary-significance test in determining whether a mark has become generic[1].

Stakeholder Views and Policy Implications

Stakeholder views on patent-eligible subject matter vary widely. Some argue that the current framework discourages innovation, particularly in emerging technologies like AI and biotechnology. Others support the exclusions on patentability, believing they help maintain a balance between innovation and public interest. The USPTO's 2019 Guidance aimed to clarify and potentially lower barriers to patentability, but its impact is still being evaluated[2].

Key Takeaways

  • Patent Claims: Clear and definite claims are essential for patent protection.
  • Patentable Subject Matter: Section 101 of the Patent Act defines what can be patented, with implicit exceptions for laws of nature, natural phenomena, and abstract ideas.
  • USPTO Guidance: The USPTO issues guidance to clarify patent eligibility, particularly for AI-related inventions.
  • AI and Patentability: Disclosure of AI tool use is required if material to patentability.
  • PAEs: These entities can significantly impact the patent landscape through licensing and litigation strategies.
  • Trademark Law: Distinctiveness is crucial for trademark registration, with descriptive marks requiring secondary meaning.

FAQs

Q: What are the categories of inventions that can be patented under Section 101 of the Patent Act? A: Section 101 allows for the patenting of any new and useful process, machine, manufacture, or composition of matter[2].

Q: How does the Alice/Mayo framework impact patent eligibility? A: The framework is a two-step test that determines if a claim is directed to an ineligible concept and if it contains an inventive concept that makes it patent-eligible[2].

Q: What is the significance of the USPTO's 2019 Guidance on patent eligibility? A: The guidance aimed to clarify and potentially lower barriers to patentability, especially for computer-related inventions, including those involving AI[2].

Q: How do AI tools affect patent drafting and inventorship? A: AI tools must be disclosed if their use is material to patentability, and human inventors must significantly contribute to the claimed invention[5].

Q: What are the two main business models of Patent Assertion Entities (PAEs)? A: Portfolio PAEs negotiate licenses for large portfolios without litigating, while Litigation PAEs often precede licensing with patent infringement suits[3].

More… ↓

⤷  Subscribe

Details for Patent 10,172,921

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Subscribe 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Subscribe 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Subscribe 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Subscribe 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 ⤷  Subscribe 2034-06-24
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 ⤷  Subscribe 2034-06-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.